SOSV

SOSV is a globally recognized deep tech venture capital firm operating at the pre-seed stage, with a primary focus on technologies advancing human and planetary health. Headquartered across key innovation hubs in New York, Newark, and San Francisco, the firm provides not only financial capital but also deeply resourced physical infrastructure — including approximately 85,000 square feet of laboratory and office space — to support early-stage founders. This hands-on model distinguishes SOSV from traditional venture capital by embedding portfolio companies within purpose-built environments designed to accelerate deep tech development.

The firm manages a portfolio of over 800 companies and has supported founders who have collectively raised $7.5 billion between 2021 and 2025. SOSV operates with an extensive co-investment network comprising more than 2,700 co-investors and 7,500 investors in its broader network. Notably, 44% of founders backed between 2021 and 2025 hold PhDs, reflecting the firm's commitment to science- and engineering-driven innovation.

SOSV operates several branded programs, including HAX — focused on hardware and deep tech — and location-specific programs under SOSV NY and SOSV SF. These accelerator programs provide structured support, mentorship, and access to lab resources for companies developing breakthrough technologies across sectors such as synthetic biology, advanced materials, robotics, food technology, and life sciences.

Portfolio companies span a wide range of deep tech verticals. Notable investments include NotCo, which uses AI to develop plant-based food alternatives; Upside Foods, a cultivated meat producer; Novoloop, which upcycles plastics into new materials; OpenTrons, which develops open-source laboratory robotics; and Ten63, an AI-driven drug discovery platform targeting previously untreatable cancers. Other portfolio companies include Smartex, applying machine vision to textile manufacturing quality control, and RxAll, which has developed handheld scanners to detect counterfeit pharmaceuticals in emerging markets.

SOSV's investment thesis centers on backing founders with deep scientific or engineering expertise who are addressing large-scale, systemic challenges. The firm's accelerator infrastructure, combined with its capital deployment at the pre-seed stage, positions it as one of the most active and resource-intensive early-stage investors in the global deep tech ecosystem.